Nicotine Uptake Following the Use of E-liquids with Different Organic Acid Salts and Nicotine Concentrations among Adult Smokers

Introduction

- Nicotine concentration, device characteristics and user behavior influence nicotine pharmacokinetics from electronic nicotine delivery systems (ENDS)¹⁻³
- When nicotine is combined with an organic acid its freebase becomes protonated and forms a salt⁴
- Evidence suggests that ENDS using nicotine salt (vs. freebase) e-liquids more efficiently deliver nicotine^{5,6}
- However, there are numerous organic acids used in ENDS products (e.g., Citric, Benzoic), and the effects of individual acids on nicotine delivery is not widely characterized
- This controlled laboratory study assessed 11 different organic acids to evaluate the effects of nicotine-salt vs. freebase formulation as well as the effect of nicotine concentration on nicotine pharmacokinetics (PK).

Results

- When nicotine concentration was held constant (at 1.5%), all nicotine-salt e-liquids except Citric acid delivered significantly more nicotine than freebase (Figures 2-3)
- Among salt formulations, Benzoic acid was greater on C_{max-BL} and AUC_{0-5-BL} than Citric acid
- Salicylic acid yielded the highest peak nicotine levels
- All nicotine-salt e-liquids, except Citric acid, had faster Tmax than freebase (Figure 4)
- All e-liquids tested had lower mean C_{max-BL} (19.5 ng/mL) and AUC_{0-5-BL} (0.60 hrs×ng/mL) than UB cigarette (Figures 2-3)

Juul Labs Science

Nicholas I. Goldenson, PhD¹, Gal Cohen, PhD¹, Patrick Bailey, PhD¹, Saul Shiffman, PhD²

Methods

- **Design** Parallel 22-arm controlled laboratory study
- Participants N=184 adult smokers (N=31-37 per arm)
- Mean age = 37.2 years (SD=10.5), 63.3% male, 55.9% white
- On average, participants smoked 14.3 cigarettes/day (SD=6.5) and smoked for 20.2 years (11.2); 7.9% had ever-used ENDS
- Materials 21 non-commercialized test e-liquids (Table 1)
- 20 nicotine-salt (11 total acids; 1.5% and 5.0% nicotine)
- 1 freebase (1.5% nicotine)



Disclosures This study was funded by Juul Labs, Inc. Authors NIG, GC, PB are full-time employees of Juul Labs, Inc.

Through PinneyAssociates, Author SS provides consulting services on tobacco harm reduction on an exclusive basis to Juul Labs, Inc.

- All e-liquids were tobacco-flavored and tested in a JUUL device
- Usual brand (UB) cigarette was used as a comparator
- Procedure nicotine PK was assessed following controlled use of test products (10 puffs) after five minutes
- Plasma nicotine concentrations were assessed 5 minutes prior-to (-5) and 1.5, 3, 5, 6, 7, 8, 10, 15, 30, 60, 90 and 120 minutes following the start of each product use
- PK endpoints were
- baseline-adjusted peak nicotine concentration (C_{max-BI}),

¹Juul Labs, Inc. ²PinneyAssociates, Inc.

- baseline-adjusted total nicotine exposure after five minutes (AUC_{0-5-BI}), and
- time to peak nicotine concentration (T____)
- Primary PK analysis tests compared each nicotine salt e-liquid to the freebase control
- C_{max-BI} and AUC_{0-5-BI} were tested using two-sample t-tests
- was tested using the Wilcoxon signed rank test

Conclusions

- All tested e-liquids delivered lower peak nicotine levels, and less nicotine in the first five minutes than cigarettes did but with comparable kinetics (except for Citric acid)
- When used in a JUUL device, e-liquids with higher nicotine concentrations (5.0% vs. 1.5%) delivered more nicotine
- Nicotine salt-based e-liquids (other than nicotine citrate) delivered statistically significantly more nicotine than did freebase e-liquids
- Nicotine exposure over the first 5 minutes from e-liquids with Benzoic acid (a variation of which is used in commercial JUULpods) was greater than Citric acid but lower than other acids (e.g., Salicylic)

References

- Blank MD, Pearson J, Cobb CO, et al. What factors reliably predict electronic cigarette nicotine delivery? Tobacco Control. 2020;29(6):644-651.
- DeVito EE, Krishnan-Sarin S. E-cigarettes: Impact of E-Liquid Components and Device Characteristics on Nicotine Exposure. Curr Neuropharmacol. 2018;16(4):438-459.
- . Jacobson K, Martinez J, Larroque S, Jones IW, Paschke T. Nicotine pharmacokinetics of electronic cigarettes: A pooled data analysis from the literature. Toxicology Reports. 2020.
- 4. Harvanko AM, Havel CM, Jacob P, Benowitz NL. Characterization of Nicotine Salts in 23 Electronic Cigarette Refill Liquids. Nicotine Tob Res. 2020;22(7):1239-1243.
- 5. O'Connell G, Pritchard JD, Prue C, et al. A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic profiles of cigarettes and e-cigarettes with nicotine salt formulations in US adult smokers. Intern Emerg Med. 2019;14(6):853-861.
- 6. Ebajemito JK, McEwan M, Gale N, Camacho OM, Hardie G, Proctor CJ. A randomised controlled single-centre open-label pharmacokinetic study to examine various approaches of nicotine delivery using electronic cigarettes. Sci Rep. 2020;10(1):19980.

This presentation is intended for sharing with the scientific community. It is not intended for advertising or promotional purposes and is not intended for a general consumer audience.

juullabsscience.com